Metropolis Healthcare Ltd Q3 FY2026 Concall Summary

Key Takeaways

• 15% revenue growth with margin expansion, despite a seasonally soft quarter: Organic EBITDA margins reached 25%, up 280 bps YoY, driven by material cost efficiencies and operating leverage, even as Q3 festive holidays and absent infection tailwinds pressured volumes.
• Strategic pivot to B2B is stabilizing the demand base: A year-long cleanup of low-quality institutional accounts and a build-out of higher-quality corporate partnerships delivered 15% B2B growth, creating a more predictable and resilient revenue stream that cushioned the seasonal B2C softness.
• Genomics is the declared next growth engine, but its margin profile is misunderstood: The new Centre of Genomics and Core Diagnostics integration unlock cross-selling of advanced oncology tests, yet genomics carries lower stand-alone gross margins than routine testing; the real payoff is higher EBITDA per patient when bundled with existing test panels.
• The consolidation thesis is back, and Metropolis is positioning as a buyer: Management declared the era of "unreasonable capital and poor unit economics" over, with financial and strategic capital now scouting for larger, high-quality acquisitions, while Metropolis continues to accumulate cash for future deals.
• What to watch next quarter: Whether Core Diagnostics hits its promised high single-digit EBITDA margin in Q4 now that genomics testing has moved in-house, the pace of lab closures and network rationalization, and any signal on a price increase that management says the market can absorb but is deferring.

Performance & Strategic Pivot

• B2C strength led by preventive and specialty: B2C revenue grew 15%, powered by TruHealth wellness packages and specialty testing, with deeper digital engagement and scientific upselling to clinicians driving adoption of advanced tests.
• B2B transformation completed: A structured cleanup of margin-dilutive institutional accounts over the past year gave way to a systematically built pipeline of better-quality corporate partnerships, with dedicated account management and faster turnaround times now delivering predictable volumes and healthier realizations.
• Tier 2/3 expansion yielding operating leverage: The hub-and-spoke network built over two years is translating into consistent volume growth and improved asset utilization, with the North region's revenue contribution rising from 9% to 17% in three quarters post-acquisitions.
• Organic margin walk: The 280 bps YoY expansion to 25% organic EBITDA margin came from material cost efficiencies, operating leverage on fixed costs, and sustained productivity initiatives; a one-time INR 9 crore Labor Code impact at the group level partially offset this.
• Core Diagnostics margin miss was a timing issue: The genomics platform launch was delayed by three months because the machine arrived in India only in January '26; tests were outsourced at lower gross margins in Q3, depressing EBITDA, but in-house testing has now begun and a meaningful Q4 improvement is expected.
• Quality infrastructure as a moat: The newly launched Internal Quality Control Index provides uniform, real-time quality benchmarks across the entire lab network, tracking the full diagnostic journey from pre-analytics to post-analytical reporting, enabling early deviation detection and rapid corrective action.

Ameera Shah: "The phase of unreasonable capital and poor unit economics seems to be over, and the phase of consolidation is back in place."

Genomics & the Core Diagnostics Integration

• Centre of Genomics established as a national reference hub: Located in Delhi post-integration, it brings high-throughput sequencing, advanced bioinformatics, and clinical interpretation capabilities for oncology, reproductive health, inherited disorders, and preventive genomics, supported by CAP-accredited labs in Gurgaon and Bombay.
• The competitive landscape is narrow: While 7–8 players exist in genomics, management contrasts this with the 3 lakh competitors in routine testing, framing genomics as a cohort with far fewer credible participants and a moat built on precision, expert interpretation, and a broad center network.
• Reliance's entry is seen as non-threatening: Management believes Reliance's genomics play is a D2C data strategy offering screening tests, not diagnostic tests; screening provides information but cannot support clinical decisions, whereas Metropolis's diagnostic-grade genomics is confirmatory and actionable.
• The margin math is about EBITDA per patient, not stand-alone margins: Genomics tests carry lower gross margins than routine tests on a stand-alone basis, but when added to an existing patient's test bundle, the incremental EBITDA per sample is significant, making the strategy one of share-of-wallet expansion rather than mix-led margin accretion.
• GLP-1 packages already launched: All planned GLP-1-related test packages are now in market, positioning Metropolis to capture demand from the growing weight-management therapeutic area.

Ameera Shah: "Genomics, if you look at the therapeutic areas which are growing the fastest in the world are actually oncology and neurology over the next 10 years, and the same situation is going to be in India. And for cancer and for any brain or nervous system areas, finally, the most important tests are going to be genomics."

Network Optimization & Capital Allocation

• Lab rationalization continues: Four labs were closed over the last two quarters, largely where duplicate facilities existed in the same town post-acquisition; a couple more closures are possible in Q4, and the year-end lab count may be slightly lower than at the quarter's start.
• Collection center density is a gradual, untimed ambition: The aspirational goal of improving from ~20–22 collection centers per lab to ~30 is a slow progression; management declined to set a timeline, arguing that directional progress matters more than hitting a specific number on a specific date.
• Capex is disciplined and network-focused: Full-year capex is estimated at INR 55–60 crores, directed toward expanding the pan-India network, upgrading IT systems, and scaling high-end equipment; no multi-year capex guidance was offered.
• Cash accumulation for M&A: Management will continue to build cash reserves to fund future growth initiatives, with the stated intent to scout for high-quality, reasonably priced acquisitions as the sector consolidates.
• Price increase deferred despite conducive conditions: Management believes the market can absorb some price increase and the environment is favorable, but is choosing to delay, observing the market and reserving the lever for an appropriate time.

AI, Innovation & Adjacencies

• AI is targeted, not transformational today: Current applications focus on enhanced test interpretation, quality monitoring, scientific selling support, and customer conversion; a pipeline of future applications spans report interpretation, clinical decision support, workflow optimization, and process automation.
• First patent secured: A patent was granted for a system monitoring and managing TB-related infections, making Metropolis one of the first listed Indian diagnostic companies to achieve this.
• Radiology is being explored cautiously: Low-end radiology (ECG, X-ray, sonography) has been scaled to a fair number of centers; high-end radiology is under consideration for a possible pilot at a couple of centers, with no timeline committed.
• Preventive health is deepening its value proposition: Over the last 3–4 quarters, Metropolis added ECG, vitals checking, and doctor consultations within health check packages, creating additional value and reinforcing the trust advantage incumbents hold over digital health-tech players who initially created the market.

Ameera Shah: "AI can play an enabling role to improve productivity and analytics. But at this time, it is unlikely to replace doctors or disrupt the industry cost structure overnight."

Volume Growth & Channel Dynamics

• Volume growth aspiration is 7–8%: Early successes on volume-driving programs are visible, and management believes this range is achievable in the coming periods, though no specific timeline was attached.
• Organic routine and semi-special growth is healthy but slower than consolidated: Consolidated routine and semi-special revenue grew 15–16%, but this includes new entities; organic routine revenue grew 12% and semi-special 9%, reflecting the base business's underlying trajectory.
• Preventive health benefits from trust, not just awareness: While digital health-tech players created the preventive health market, management argues that the most important component is consumer trust in the incumbent brand, which has allowed Metropolis to capture disproportionate benefit from rising awareness and improving affordability.

Ameera Shah: "I think in health care, we'll often find that, like you said, even though the market was created by the sort of digital health tech players, finally, the most important component is trust, consumer trust."

Guidance & Commitments

Key Metrics